Hansoh’s Weiyong Sun: Roche deal part of strategy to capture more upside

BioCentury reported that Hansoh Pharmaceutical CBO Weiyong Sun said the company's collaboration with Roche is part of a shift from single-asset licensing to co-development arrangements, with Hansoh willing to take on more clinical development risk in exchange for a larger share of future profits. The agreement covers two of Hansoh's preclinical ADC programs, plus multiple programs based on Roche-proposed targets advanced through Hansoh's ADC platform.